VectorY NV, a developer of vectorised antibody therapies to treat neurodegenerative diseases, has appointed Khurem Farooq as an independent board member. Mr Farooq is currently chief executive officer at Aiolos Bio whose acquisition by GSK was announced in January. Previously Farooq was CEO of Gyroscope, which was acquired by Novartis in 2021, and senior vice president of the immunology and ophthalmology business unit at Genentech, part of the Roche group. His appointment follows VectorY’s $138 million Series A round announced in November 2023 to support clinical development of the company’s lead programme for amyotrophic lateral sclerosis. Mr Farooq has a BSc in biological sciences from the University of Wolverhampton and an MBA from Aston University, both in the UK.
VectorY announced the appointment on 18 January 2024.
Copyright 2024 Evernow Publishing Ltd